SRR934802
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 8.639947437582128
- age_years
- 63
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.757
- INTERFERON_GAMMA_RESPONSE+0.661
- E2F_TARGETS+0.593
- G2M_CHECKPOINT+0.569
- ALLOGRAFT_REJECTION+0.562
- IL6_JAK_STAT3_SIGNALING+0.531
- MYC_TARGETS_V1+0.510
- PROTEIN_SECRETION+0.462
- INFLAMMATORY_RESPONSE+0.439
- TGF_BETA_SIGNALING+0.431
Top 10 suppressed
- KRAS_SIGNALING_DN-0.389
- PANCREAS_BETA_CELLS-0.385
- MYOGENESIS-0.175
- SPERMATOGENESIS-0.139
- OXIDATIVE_PHOSPHORYLATION-0.088
- ESTROGEN_RESPONSE_EARLY-0.081
- WNT_BETA_CATENIN_SIGNALING-0.060
- ESTROGEN_RESPONSE_LATE-0.044
- APICAL_SURFACE-0.021
- BILE_ACID_METABOLISM-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934925 | — | — | 0.967 |
| 2 | 62966348-1C16-4A6D-AA82-707B3F759D5C | — | — | 0.963 |
| 3 | SRR934753 | — | — | 0.961 |
| 4 | 8B4E465B-0FD5-4154-824B-1E6B2656FD2F | — | — | 0.955 |
| 5 | SRR934730 | — | — | 0.954 |
| 6 | SRR934722 | — | — | 0.954 |
| 7 | SRR934895 | — | — | 0.950 |
| 8 | SRR934837 | — | — | 0.947 |
| 9 | SRR934737 | — | — | 0.945 |
| 10 | SRR934932 | — | — | 0.944 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.757 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.661 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.593 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.569 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.562 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.531 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.462 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.439 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.431 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.423 | Inavolisib | — uncovered |
| APOPTOSIS | 0.411 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.411 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.398 | Inavolisib | — uncovered |
| COMPLEMENT | 0.393 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.391 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.382 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.378 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.369 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.358 | Inavolisib | — uncovered |